DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES

• Main Authors: CHU, YU-WAYE, WANG, HONG, SIMKO, STEPHEN JAMES III, TOTPAL, KLARA, WEI, MICHAEL C, YIN, SHEN, BENDER, BRENDAN CHRISTIAN, CHEN, XI, LI, CHIUNG, TO, IRIS TRANTHUYNGAN, HRISTOPOULOS, MARIA, O'HEAR, CAROL ELAINE
• Format: Patent
• Language: English; French
• Published: 12.05.2022
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate. La présente invention concerne le traitement de sujets ayant des troubles prolifératifs cellulaires CD20-positifs (par ex., des troubles prolifératifs des lymphocytes B, tels que les lymphomes non hodgkiniens). Plus spécifiquement, l'invention concerne le traitement de sujets ayant un trouble prolifératif cellulaire CD20-positifs (par ex., un trouble prolifératif des lymphocytes B) par administration d'une combinaison d'un anticorps bispécifique anti-CD20/anti-CD3 et d'un conjugué anticorps anti-CD79b-médicament.